イーライリリー、AI創薬企業インシリコ・メディシンと275億ドルの契約を締結
本文の状態
日本語全文を表示中
詳細モードで約1分の本文を読めます。
同じ出来事の情報源
この情報源を基点に整理
The Decoder
米製薬大手イーライリリーは、香港上場のAI創薬企業インシリコ・メディシンと275億ドルの契約を結び、AI駆動の創薬開発に大規模投資を行う。
Source Article
元記事を日本語で読む
本文に関係しない購読案内、埋め込み通知、サイト内プロモーションは除いています。
米国の製薬大手イーライ・リリーは、AI（人工知能）を駆使した創薬開発に巨額を投じ、香港上場企業のインシリコ・メディシンと275億ドル規模の契約を結びました。
この記事「Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine」は、The Decoderに最初に掲載されました。
原文を表示
Mar 29, 2026
Eli Lilly has signed a $2.75 billion deal with Hong Kong-listed AI pharmaceutical company Insilico Medicine. The partnership aims to bring AI-developed drugs to the global market. Insilico will receive $115 million upfront, with the rest tied to regulatory and commercial milestones as well as license fees, both companies announced.
According to founder and CEO Alex Zhavoronkov, Insilico has developed at least 28 drugs using generative AI, with nearly half already in clinical trials. The two companies have been working together since 2023.
Zhavoronkov told CNBC that Lilly actually outperforms Insilico in some areas of AI. Andrew Adams of Lilly called Insilico's AI research "a powerful complement" to its own clinical development efforts. Insilico is building its AI capabilities in Canada and the Middle East, while early drug development takes place in China. Eli Lilly is also working with a Deepmind subsidiary on AI-driven medicine.
AI News Without the Hype – Curated by Humans
Subscribe to THE DECODER for ad-free reading, a weekly AI newsletter, our exclusive "AI Radar" frontier report six times a year, full archive access, and access to our comment section.
Subscribe now
今日のまとめ
AIデイリーブリーフで今日の重要ニュースをまとめ読み